Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 91,690 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 91,690 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1.50, for a total value of $137,535.00. Following the completion of the transaction, the insider directly owned 48,750 shares in the company, valued at approximately $73,125. The trade was a 65.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Daljit Singh Aurora also recently made the following trade(s):

• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total value of $51,014.70.
• On Wednesday, August 19th, Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total value of $51,150.00.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total transaction of $82,524.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,987 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.59, for a total transaction of $55,629.33.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.58, for a total transaction of $53,975.96.

Neumora Therapeutics Price Performance

Neumora Therapeutics stock remained flat at $1.64 during trading hours on Wednesday. 716,090 shares of the company’s stock were exchanged, compared to its average volume of 699,708. The company has a debt-to-equity ratio of 1.19, a quick ratio of 5.09 and a current ratio of 4.50. Neumora Therapeutics, Inc. has a 52 week low of $0.83 and a 52 week high of $3.65. The company’s 50-day moving average price is $1.61 and its 200 day moving average price is $2.11.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, analysts forecast that Neumora Therapeutics, Inc. will post -0.85 earnings per share for the current year.

Key Stories Impacting Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.89 from $1.29 and its FY2027 forecast to a loss of $0.68 from $1.25, indicating analysts expect substantially narrower losses over the next two years.
• Positive Sentiment: The firm also improved its quarterly outlook, forecasting a Q3 2026 loss of $0.20 per share versus $0.32 previously and a Q4 2026 loss of $0.16 versus $0.30 previously.
• Positive Sentiment: Longer-term estimates were upgraded sharply: FY2028’s projected loss narrowed to $0.52 from $1.10, FY2029 moved to projected profit of $0.20 from a $0.26 loss, and FY2030 profit expectations increased to $1.83 from $1.51 per share. These changes imply a faster potential transition to profitability.
• Positive Sentiment: HC Wainwright’s current estimates call for losses of $0.15, $0.16, $0.19 and $0.17 per share in the first four quarters of 2027, respectively, with full-year 2027 losses of $0.68. The firm’s continued Buy rating provides additional support for investor sentiment.
• Neutral Sentiment: Neumora remains unprofitable, with the broader current-year consensus at a loss of $0.93 per share. The company’s shares are trading well below their 200-day moving average and remain near the lower portion of their 12-month range, underscoring continued execution and financing risks despite the improved forecasts.

Wall Street Analyst Weigh In

NMRA has been the subject of a number of recent analyst reports. Needham & Company LLC reduced their target price on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Royal Bank Of Canada reduced their price objective on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Wall Street Zen raised shares of Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Finally, Mizuho dropped their target price on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $6.57.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NMRA. Wellington Management Group LLP purchased a new position in Neumora Therapeutics during the second quarter worth $27,519,000. Bank of America Corp DE acquired a new position in Neumora Therapeutics in the 2nd quarter valued at about $171,000. ADAR1 Capital Management LLC purchased a new position in Neumora Therapeutics in the 2nd quarter valued at about $357,000. Canada Pension Plan Investment Board purchased a new stake in shares of Neumora Therapeutics during the second quarter worth about $337,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Neumora Therapeutics in the second quarter valued at approximately $44,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.